» Articles » PMID: 9582015

TP53 DNA Contact Mutations Are Selectively Associated with Allelic Loss and Have a Strong Clinical Impact in Head and Neck Cancer

Overview
Journal Oncogene
Date 1998 May 15
PMID 9582015
Citations 38
Authors
Affiliations
Soon will be listed here.
Abstract

Recent studies have suggested that different mutation types within the core domain of the tumour suppressor protein p53, i.e. DNA contact mutations and structural mutations, confer different biological properties. We have analysed in 86 head and neck squamous cell carcinomas (HNSCC), whether these p53 mutation types have a differential clinical impact. Thirty-seven missense mutations were identified. Thirteen of these (36%) were DNA contact mutations, occurring in the L3 loop, in the H2 loop sheet helix motif, in the S10 beta strand and in Zinc binding residues. Microsatellite marker analysis revealed a selective association between these mutations and the loss of wild-type alleles (100% LOH vs 50% LOH in tumours with structural mutations; P=0.0034, Fisher's exact, 2-tailed). In comparison to structural mutations or to the absence of mutations in the core domain, DNA contact mutations were associated with higher tumour stages (84.6% vs 62%), a higher incidence of lymph node metastasis (91.7% vs 56%; P=0.014, Fisher's exact, 2-tailed), a shortened recurrence-free survival (8.1 months vs 23.7 months, P=0.047, log rank test) and overall survival (11 months vs 29.2 months; P=0.003, log rank test). The latter was also the case when only stage IV tumours were analysed (P=0.0055, log rank test). These data indicate that in HNSCC, TP53 DNA contact mutations confer a strong selection pressure to eliminate wild-type alleles, and that they result in an accelerated tumour progression and reduced therapeutic responsiveness.

Citing Articles

Evolutionary Action Score of Analysis in Pathologically High-Risk Human Papillomavirus-Negative Head and Neck Cancer From a Phase 2 Clinical Trial: NRG Oncology Radiation Therapy Oncology Group 0234.

Michikawa C, Torres-Saavedra P, Silver N, Harari P, Kies M, Rosenthal D Adv Radiat Oncol. 2022; 7(6):100989.

PMID: 36420184 PMC: 9677209. DOI: 10.1016/j.adro.2022.100989.


Molecular margins in head and neck cancer: Current techniques and future directions.

Stepan K, Li M, Kang S, Puram S Oral Oncol. 2020; 110:104893.

PMID: 32702629 PMC: 8131031. DOI: 10.1016/j.oraloncology.2020.104893.


Expression levels of miR-34-family microRNAs are associated with TP53 mutation status in head and neck squamous cell carcinoma.

Metheetrairut C, Chotigavanich C, Amornpichetkul K, Keskool P, Ongard S, Metheetrairut C Eur Arch Otorhinolaryngol. 2018; 276(2):521-533.

PMID: 30515607 DOI: 10.1007/s00405-018-5223-x.


Mutational profiling can identify laryngeal dysplasia at risk of progression to invasive carcinoma.

Manterola L, Aguirre P, Larrea E, Arestin M, Gaafar A, Elorriaga K Sci Rep. 2018; 8(1):6613.

PMID: 29700339 PMC: 5919930. DOI: 10.1038/s41598-018-24780-7.


The tumor suppressor capability of p53 is dependent on non-muscle myosin IIA function in head and neck cancer.

Coaxum S, Tiedeken J, Garrett-Mayer E, Myers J, Rosenzweig S, Neskey D Oncotarget. 2017; 8(14):22991-23007.

PMID: 28160562 PMC: 5410280. DOI: 10.18632/oncotarget.14967.